Appeal 2006-2945
Application 10/041,958
3. Teaches “passive immunization of a human or animal against SLT
toxinemia comprising administering to the human or animal a
prophylactically effective amount of the elicited antibody” (Answer 3-4).
4. Teaches “that SLT toxinemia can lead to hemolytic uremic syndrome”
(Answer 4).
5. Teaches that their “‘invention provides an antitoxin to one or more
SLTs’” (id.).
6. Teaches “that ‘[a] single type of SLT, such as SLT-II or a variant thereof,
such as SLT-IIvp can be injected [and that] [t]his provides polyclonal
antibodies that are monospecific to just that type of SLT or variant’” (id.).
Perera:
7. Teaches “five monoclonal antibodies which bind to the α-subunit of SLT-
II and were able to neutralize the toxin” (id.).
Williams:
8. Teaches that “‘[s]tudies of Shiga toxin B subunit suggest that neutralizing
epitopes may also be present at both the N- and C-terminal regions of VT1
and VT-2 B subunits [and that] [p]olyclonal antibodies raised against
peptides from these regions . . . show partial neutralization of Shiga toxin . .
.’” (id.).
9. Teaches that “VT1 and VT2 correspond to SLT-1 and SLT-II” (id.).
5
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: September 9, 2013